BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20566392)

  • 1. Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine.
    Stittelaar KJ; Lacombe V; van Lavieren R; van Amerongen G; Simon J; Cozette V; Swayne DE; Poulet H; Osterhaus AD
    Vaccine; 2010 Jul; 28(31):4970-6. PubMed ID: 20566392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
    Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
    Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.
    Park KS; Lee J; Ahn SS; Byun YH; Seong BL; Baek YH; Song MS; Choi YK; Na YJ; Hwang I; Sung YC; Lee CG
    Virology; 2009 Dec; 395(2):182-9. PubMed ID: 19836045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live vaccination with an H5-hemagglutinin-expressing infectious laryngotracheitis virus recombinant protects chickens against different highly pathogenic avian influenza viruses of the H5 subtype.
    Pavlova SP; Veits J; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Aug; 27(37):5085-90. PubMed ID: 19573638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
    Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ; Ross TM
    Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Construction and experimental immunity of recombinant replication-competent canine adenovirus type 2 expressing hemagglutinin gene of H5N1 subtype tiger influenza virus].
    Gao YW; Xia XZ; Wang LG; Liu D; Huang G
    Wei Sheng Wu Xue Bao; 2006 Apr; 46(2):297-300. PubMed ID: 16736595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes.
    Wu J; Zhang F; Fang F; Chang H; Wang F; Yang Z; Sun B; Chen Z
    Vaccine; 2010 Mar; 28(15):2775-81. PubMed ID: 20117261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
    Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
    J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.
    Droebner K; Haasbach E; Fuchs C; Weinzierl AO; Stevanovic S; Büttner M; Planz O
    Vaccine; 2008 Dec; 26(52):6965-74. PubMed ID: 18848593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
    Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.